SUMATRIPTAN INJECTION, USP SOLUTION

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

SUMATRIPTAN (SUMATRIPTAN SUCCINATE)

Sẵn có từ:

DR REDDY'S LABORATORIES LTD

Mã ATC:

N02CC01

INN (Tên quốc tế):

SUMATRIPTAN

Liều dùng:

6MG

Dạng dược phẩm:

SOLUTION

Thành phần:

SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 6MG

Tuyến hành chính:

SUBCUTANEOUS

Các đơn vị trong gói:

100

Loại thuốc theo toa:

Prescription

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0123238006; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2022-10-28

Đặc tính sản phẩm

Page 1 of 37
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
SUMATRIPTAN INJECTION, USP
6 mg / 0.5 mL (as sumatriptan succinate)
Subcutaneous Injection and Autoinjector
5-HT
1
Receptor Agonist
Migraine Therapy
Manufactured by :
Dr. Reddy’s Laboratories Ltd.,
Bachupally -500 090 India
Imported and Distributed by :
Dr. Reddy’s Laboratories Canada Inc.,
Mississauga, ON, L4W 4Y1 Canada
Date of Preparation:
October 26, 2022
Submission Control Number: 249687
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
Table of Contents
1 INDICATIONS
....................................................................................................................................
4
1.1
Pediatrics
....................................................................................................................................
4
1.2
Geriatrics
....................................................................................................................................
4
2 CONTRAINDICATIONS .....................................................................................................................
4
4 DOSAGE AND ADMINISTRATION ....................................................................................................
5
4.1
Dosing Considerations
................................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.............................................................................
5
4.4 Administration
...........................................................................................................................
6
5 OVERDOSAGE .................................................................................................................................
6
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .............................................. 6
7 WARNINGS AND PRECAUTIONS
........................................